See the DrugPatentWatch profile for enbrel
Enbrel and Respiratory Infections: What's the Risk?
Enbrel, a biologic medication used to treat various autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis, has been linked to an increased risk of respiratory infections in some patients.
Tuberculosis and Respiratory Infections: A Known Concern
Enbrel contains an active ingredient called etanercept, which has been associated with an increased risk of developing tuberculosis (TB) [1]. According to the medication's labeling, patients treated with Enbrel may be at a higher risk of TB infection, especially in regions with a high TB prevalence. It is essential for healthcare providers to screen patients for latent TB before starting Enbrel treatment.
Other Respiratory Infections: What's the Risk?
While TB is a known concern with Enbrel, data also suggest an increased risk of other respiratory infections, including pneumonia and bronchitis. A clinical trial involving 3,400 patients with psoriatic arthritis or psoriasis found that Enbrel was associated with a higher risk of respiratory tract infections compared to a placebo group [2]. Patients with pre-existing respiratory issues, such as asthma or chronic obstructive pulmonary disease (COPD), may be more susceptible to complications.
Patient Factors that Increase Risk
Several factors can increase the risk of respiratory infections in Enbrel-treated patients, including:
* Age (patients over 65 years)
* History of respiratory disease (e.g., asthma, COPD)
* Weakened immune system
* Use of immunosuppressive medications
* Smoking
Monitoring and Management
Healthcare providers should closely monitor patients taking Enbrel for signs of respiratory infections and adjust treatment accordingly. Patients should also be advised to seek medical attention promptly if they experience symptoms such as fever, cough, or shortness of breath.
Patent Information and Generics
The Enbrel patent is set to expire in 2026 [3], potentially allowing for the development of biosimilars. However, it is unclear whether biosimilars will pose the same risks as the original medication. Researchers will need to conduct further studies to assess the safety profile of biosimilars in this context.
Sources:
[1] Enbrel labeling (May 2023). Pfizer.
[2] McInnes IB, et al. Safety and efficacy of etanercept in patients with psoriatic arthritis: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2007; 56(10): 3190-3197.
[3] DrugPatentWatch.com. (2023). Enbrel (Etanercept) Patents.